Real cases make the trade-offs concrete. Two oncologists walk through actual breast and prostate cancer patients, pairing the conventional standard of care with an integrative, terrain-focused layer. Dr. Ray Page covers the diagnosis, staging, and multimodality treatment of triple-negative breast cancer and the patient factors that shape each decision, while Dr. Jamie Waselenko adds root-cause assessment and support through biopsies, scans, and therapy, then extends the approach to high-grade prostate cancer. It’s shared decision-making shown rather than described.

Learning objectives

By the end of this session, participants will be able to:

1. Review the diagnosis, staging, and risk stratification of triple-negative breast cancer, including the role of pathology, imaging, and germline BRCA testing.
2. Describe evidence-based multimodality treatment options for early-stage triple-negative breast cancer, including neoadjuvant chemoimmunotherapy, surgery, radiation, and adjuvant systemic therapy.
3. Apply patient-specific factors, including comorbidities and residual disease after neoadjuvant therapy, to guide shared decision-making and optimize breast cancer treatment planning.
4. Integrate terrain analysis (root-cause assessment and remediation) into breast cancer care, including supporting the patient through biopsies, scans, ADT, chemotherapy, and radiation therapy.
5. Describe the workup and risk stratification of high-grade, oligometastatic prostate cancer.
6. Discuss standard treatment options for metastatic castration-sensitive prostate cancer, including ADT, AR pathway inhibitors, radiation, and metastasis-directed therapy.
7. Recognize patient-specific factors that affect treatment tolerance and shared decision-making in prostate cancer care.